For in vivo rodent research: BPC-157 : 10 g/kg/day subcutaneous or intraperitoneal, 2-4 weeks TB-500 : 2-3 mg cumulative over 2-3 injections per week, 4-6 weeks Stack : same independent doses, separate or combined injections Clinical human protocols have not yet been standardized the few phase I/II trials used doses empirically derived from animal models
GLP-1 is a peptide hormone consisting of 30 amino acids derived from glucagonogen, which is processed by the differentiation of the glucagonogen gene expressed by intestinal epithelial endocrine L-cells, and has two biologically active forms, GLP-1 (736 amide) and GLP-1 (7-37), and the intestine is the major source of GLP-1 in plasma (Holst, 2007)
Browse all Peptides & GLP-1 education Frequently Asked Questions How is tirzepatide different from semaglutide
Lancet Diabetes Endocrinol 7:344355 Mozaffarian D (2024) GLP-1 agonists for obesityA new recipe for success
Everyone is different though and the most successful patients also work hard to make diet and lifestyle changes
When prescribed for weight management, however, coverage becomes less consistent